Time Stamps

[00:44] — Introduction to the Nucleate podcast and Mikael Dolsten.

[02:42] — Mikael shares his upbringing and academic journey at Lund University, highlighting the influence of mentors.

[05:46] — Transitioning from academia to the pharmaceutical industry, driven by curiosity and patient needs.

[19:18] — Reflecting on the pressures and leadership style of managing thousands of scientists at Pfizer.

[39:56] — Highlights of vaccine development, particularly Pfizer’s role in COVID-19 vaccines and global impact.

[51:09] — Behind the scenes of developing Paxlovid during COVID-19 and Mikael’s personal connection to the pandemic.

[1:05:15] — Traits Mikael looks for in founders: the value of humility, talent, and collaborative culture.

[1:12:05] — How to support early-stage biotech companies while maintaining entrepreneurial spirit and adaptability.

[1:13:41] — Mikael’s insights into the evolving role of AI in drug discovery and precision medicine.

[1:23:32] — Rapid-fire Q&A: personal reflections, career advice, and influences outside of science.

In this episode, Allyson Berent, Chief Science Officer, Foundation For Angelman Syndrome Therapeutics (FAST), shares her remarkable journey from a career in veterinary medicine to becoming a leading advocate and innovator in the field of rare disease drug development, inspired by her daughter’s diagnosis with Angelman syndrome. She recounts the challenges of obtaining an early diagnosis, the emotional impact on her family, and her determination to find solutions where none existed. Allison describes how she immersed herself in scientific research, connected with experts, and joined the Foundation for Angelman Syndrome Therapeutics, eventually helping to launch and lead multiple initiatives aimed at accelerating the development of transformative therapies for Angelman syndrome and similar neurodevelopmental disorders.

Throughout the conversation, Allison emphasizes the importance of true patient-focused drug development, sharing how her personal experience shaped her approach to building companies, running clinical trials, and fostering collaboration across the biotech ecosystem. She offers practical advice for entrepreneurs and executives, urging them to listen to patients and families, remain humble, and surround themselves with experts to address knowledge gaps. This episode highlights the profound impact that new therapies are having on patients’ lives and underscores the value of mission-driven innovation in advancing treatments for rare diseases.

Time Stamps

00:02 – Introduction and Allison’s upbringing and early interest in veterinary medicine.

00:15 – Allison shares the story of how she decided to become a vet and her educational journey.

01:34 – She discusses her career as a vet, starting a family, and her daughter’s diagnosis with Angelman syndrome.

04:36 – Allison describes the early signs, medical consultations, and the process of getting a diagnosis for her daughter.

11:22 – Sam and Allison discuss the challenges of delayed diagnosis and the importance of proactive care.

13:01 – She shares stories from the community and changes in genetic testing practices.

0:14:35 – Allison explains how she and her family responded to the diagnosis and her drive to find solutions.

18:18 – She describes connecting with the foundation, joining the board, and developing a roadmap for a cure.

26:15 – The process of moving from mouse model research to human clinical trials, raising funds, and starting a company.

31:12 – Discussion on what true patient-driven development means and how it shaped Allison’s approach.

39:07 – Allison details the journey of the company, partnership with Ultragenyx, and the impact of the acquisition.

45:49 – Explanation of the accelerator model, portfolio companies, and collaborative approach to drug development.

51:20 – How the accelerator shares resources and knowledge across programs and with other companies.

52:24 – Quincy’s Progress and the Impact of New Therapies,participation in clinical trials, and the real-world impact on families.

56:05 – Sam and Allison discuss the life-changing effects of new treatments for Angelman syndrome.

58:56 – Allison offers advice on keeping the patient at the center of drug development and listening to families.

1:06:13 – She shares suggestions for integrating patient stories and perspectives into company culture and meetings.

1:09:14 – Final Words of Wisdom for Entrepreneurs: Allison emphasizes humility, gap analysis, teamwork, and resilience for those starting companies.

1:11:53 – Conclusion and Thanks

In our latest episode of the Nucleate Podcast, we sit down with Joe Horsman, Investor at Madrona VC, to explore his unique path from academic researcher to biotech operator and ultimately to venture capital.

Joe shares how growing up in Seattle shaped his passion for science, why he pursued a PhD in biochemistry, and what it took to stand out when transitioning into industry. From early roles at NanoString and Stratos Genomics to the Roche acquisition, he reflects on lessons learned across startups and large companies alike.

We talk about:

🔹 His transition from academia to industry and the importance of differentiating a PhD resume

🔹 Lessons from NanoString, Stratos Genomics, and the Roche acquisition

🔹 Navigating culture shifts from startup to big pharma

🔹 Madrona’s investment thesis at the life sciences–tech intersection

🔹 How AI and data science are reshaping the drug development lifecycle

This one’s for anyone curious about where biotech meets computer science, and what it takes to build companies that endure

In this episode of the Nucleate Podcast, Armon Sharei shares his journey from early life experiences in California, Iran, and Dubai to pursuing higher education at Stanford and MIT, ultimately leading to a career at the intersection of science and entrepreneurship. The conversation explores his motivations to make a positive impact on the world, the transition from academia to founding his first company Squeeze: a company based on innovative cell engineering technology and the challenges of navigating the biotech industry. Armon discusses the evolution of Squeeze from a platform to a therapeutics company, the difficulties of convincing investors and industry veterans, and the high-stakes decisions that shaped the company’s fate, including a major strategic pivot and the eventual fallout with the board. The episode also delves into personal and professional lessons learned, including the impact of a cancer diagnosis, the importance of safety and quality of life in drug development, and the value of mentorship and betting on talent. After Squeeze's liquidation, Armon founded Portal Biotechnologies, applying hard-earned lessons to focus on enabling broad innovation in cell therapy through platform technology. The discussion highlights the realities of biotech entrepreneurship, the significance of resilience, and the ongoing mission to empower others in the field, all while balancing personal passions and family life. 

Episode Notes: 

00:00- Kicking off the episode and setting the stage 

02:25- Armon shares a quick overview of his journey 

03:24- He reflects on growing up in California, Iran, Dubai, and the US and how it shaped his worldview 

05:13- Armon talks about his early love for science and how he chose his career path 

06:26- Diving into Armon’s first big ideas and research interests 

08:14- Armon discusses the shift from scientist to entrepreneur 

10:47- How Squeeze was born. Armon shares the story behind the tech and his PhD research 

13:58- Mapping the journey: PhD, founding Squeeze, and postdoc life 

18:45- Armon opens up about the challenges of being a young biotech founder and raising early funding 

22:53- He explains the strategic pivot from platform tech to therapeutics 

26:40- Highlighting key wins: investor interest and the Roche partnership 

20:01- Armon shares the tough moments — going public, market shifts, and internal debates 

34:34- Navigating board decisions, layoffs, and the fallout with Roche 

36:34- Armon reflects on leaving Squeeze and the emotional toll it took 

40:27- Starting Portal: Armon shares what motivated him to begin again 

44:27- Armon opens up about his cancer diagnosis and how it changed his perspective 

49:03- Lessons from being a patient, Armon talks about safety and quality of life in drug development 

51:11- He shares broader insights on industry incentives, pricing, and systemic challenges 

54:10- What makes Portal’s tech unique? Armon breaks down its competitive edge 

56:57- Real-world use cases and early adopters of Portal’s platform 

1:00:21- Armon discusses the long-term vision: platform-first vs. therapeutics 

1:03:49- Armon highlights the importance of mentorship and betting on talent 

1:09:33- He talks about balancing work, life, and personal passions

In this episode of the Nucleate Podcast, we are joined by Prof. Dr. Dominik Rüttinger — oncological surgeon, MD/PhD, and Global Head of Research & Early Development Oncology at Bayer Pharmaceuticals. We talk about his journey from the operating room to biotech startups and global pharma leadership, navigating a 10% success rate in oncology drug development, building unbiased decision frameworks for high-stakes calls, the realistic role of AI in drug discovery and clinical trials, balancing quality of life versus longevity in cancer treatment, and his vision for the future of prevention, early detection, and personalized medicine. Whether you’re a scientist, innovator, or leader, this conversation will challenge how you think about risk, decision-making, and impact in healthcare. 

Episode Chapters: 

• 00:00 Intro 
• 02:30 Dominik talks about his childhood, family background, and early influences that led him toward science 
• 04:45 Dominik explains his decision to pursue both medicine and science, describing how his medical school and PhD experiences overlapped 
• 07:30 Offering early career advice, Dominik talks about the importance of aiming high, questioning the status quo, and embracing a bit of naivete 
• 11:06 Dominik discusses why he chose oncology and how interdisciplinary training shaped his career 
• 16:45 Dominik describes his transition from academia to industry, sharing his motivations and the decision-making process behind the move 
• 20:02 Reflecting on his adjustment to industry, Dominik highlights the differences in work environment and expectations compared to academia 
• 23:33 Dominik provides practical tips for others transitioning from academia to industry, emphasizing humility and the value of building a diverse “toolbox” of skills 
• 28:01 Dominik talks about moving from a startup to a large company, and how his responsibilities shifted to managing a broader portfolio 
• 33:28 Dominik describes what his daily life looks like as a portfolio leader in oncology R&D and the types of decisions he makes regularly 
• 37:24 Dominik delves into the challenges of decision-making in drug development, discussing success rates and the importance of a “10% mindset.” 
• 39:27 Dominik explains the impact of biases in drug development and how organizations use frameworks to make more objective decisions 
• 42:46 Dominik shares his perspective on the role of AI in drug development and how it can support better decision-making 
• 47:02 Dominik discusses the use of AI in clinical trials and considers whether it can make development faster and less expensive 
• 51:46 Drawing on his clinical experience, Dominik talks about patient care and patient perspectives, especially the balance between quality of life and longevity in cancer treatment 
• 55:38 Dominik looks to the future of cancer prevention, early detection, and prediction, and how these areas might evolve

In this episode of the Nucleate Podcast, Armand Cognetta, founder and CEO of General Proximity, shares his compelling journey from a directionless college student to a biotech entrepreneur. Drawing from personal experiences of academic struggles and scientific curiosity, Armand discusses how his passion for chemical biology and small molecule drug discovery led him to create a groundbreaking proximity therapeutics platform. He candidly explores the challenges of startup life, including early fundraising difficulties, imposter syndrome, and the critical importance of persistence, grit, and maintaining a high bar for talent. Throughout the conversation, Armand emphasizes the value of working on ambitious, world-changing ideas, the power of proximity in biological systems, and the need for founders to stay focused, resilient, and mission-driven. His story is a testament to the transformative potential of scientific innovation and entrepreneurial spirit, offering inspiration for young scientists and aspiring founders navigating the complex landscape of biotech startups.

Time Stamps

00:00 – Intro 

03:12 – Growing up in northern Florida 

06:44 – Taking a year off college due to poor grades 

07:05 – A transformative internship experience 

08:33 – Paul Graham’s blog & early obsession with tech 

11:25 – Learning persistence through failure 

20:06 – How to generate and evaluate startup ideas 

36:02 – What is General Proximity? 

53:15 – Impostor syndrome & early founder struggles 

1:02:00 – How past failures prepared him 

1:05:53 – Recruiting and retaining talent in startups 

1:09:57 – Biotech vs. tech: hiring challenges 

1:16:28 – Building an effective advisory board 

1:19:46 – Advice for aspiring founder-scientists 

1:22:00 – Final thoughts on entrepreneurship & ambition

From science to startup: real talk on biotech founding paths. For many early-stage biotech founders, that’s where the real challenge begins—and that’s where Persephoni Bio Partners comes in. In this episode of the Nucleate Podcast, Hillary Schultz and Dr. William Heath share how their unique journeys from clinical medicine and pharmaceutical R&D to early-stage investing led them to co-found Persephoni Bio, a venture studio focused on transforming breakthrough science into scalable biotech companies. Hillary and William reveal the most overlooked reasons biotech startups struggle, highlighting that success often hinges more on the team than the technology. They offer candid insights into IP strategy, founder dynamics, and patient-centered development, while also emphasizing the importance of resilience, adaptability, and a growth mindset.

For anyone navigating the next step after Nucleate, this episode offers practical guidance and inspiration for building biotech that lasts! 

Time Stamps

• Personal Background and Motivation: 
  • 0:03:40 - Hillary discusses her early passion for heathcare and impact
  • 0:07:07 - William explains his journey into science, starting from childhood
• Nucleate Experience: 
  • 0:14:12 - Hillary's advice on making the most of Nucleate
  • 0:16:45 - William's perspective on Nucleate's value
• Persephoni Bio Partners:
  • 0:26:09 - Hillary explains the founding of Persephoni
  • 0:28:56 - William discusses the mission of supporting early-stage biotech
• IP and Technical Challenges:
  • 0:47:48 - Discussion on IP strategies for startups
  • 0:57:11 - Technical challenges in biotech development
  • 0:58:39 - Importance of understanding patient needs
• Entrepreneurship Advice:
  • 1:02:11 - Advice for Nucleate Activator program graduates
  • 1:05:00 - Discussing entrepreneurial mindset and resilience
  • 1:07:24 - Embracing failure as a learning opportunity
• Personal Balance: 
  • 1:10:47 - Hillary and William discuss work-life balance
  • 1:13:47 - Importance of team dynamics in success

Follow us at https://signal.nucleate.xyz

0:03:41 - Dr. Pao discusses losing his father to colon cancer at age 13, which motivated his career in medicine

0:05:30 - Describes his early academic training, including his PhD work on Gamma Delta T cells

0:09:54 - Begins discussing the EGFR mutation discovery in lung cancer research 0:13:16 - Shares the story of being "scooped" by other researchers when publishing his EGFR mutation findings

0:32:44 - Starts discussing his book "Breakthrough: The Quest for Life-Changing Medicines"

0:42:35 - Tells the serendipitous story of Tylenol's discovery

0:58:38 - Begins discussing entrepreneurship and decision-making in drug development

1:04:29 - Talks about starting his own company, Revelio Therapeutics

1:11:28 - Discusses future trends in medical research and potential breakthrough areas

1:15:52 - Offers final advice about resilience for aspiring entrepreneurs and scientists These timestamps highlight key moments in the conversation about Dr. Pao's career, research, book, and insights into medical innovation.

Follow us at https://signal.nucleate.xyz/

[0:00] Peter begins by discussing his upbringing in a New Zealand university town.

[2:39] He realizes he is not suited for bench work during his PhD and discovers a passion for computational analysis.

[4:30] Campbell joins the Sanger Institute and participates in one of the first cancer genome sequencing projects using new technology.

[8:00] He describes the revolutionary period of cancer genomics from 2008 to 2015, systematically exploring genetic changes in cancers.

[12:32] Campbell shifts research focus to studying mutations in normal tissues across different organ systems.

[13:44] Flagship Pioneering reaches out to discuss the potential clinical relevance of their research.

[14:56] He co-founds Quotient Therapeutics with Flagship Pioneering to explore therapeutic applications of somatic mutation research.

[20:39] Campbell explains the evolutionary process of mutations in cells, comparing it to natural selection.

[26:49] He discusses the incredible genetic diversity within a single individual's cell populations.

[35:12] The conversation explores the potential for personalized medicine based on genetic mutation analysis.

[39:55] Campbell explains how cells adapt to environmental changes and potentially revert mutations when pressures are removed.

[49:29] He describes Quotient's approach to identifying and potentially targeting specific mutations.

[58:47] Campbell discusses the partnership with Pfizer in cardiovascular and renal disease research.

[1:08:01] He compares the differences between academic and startup research environments.

[1:15:39] Campbell offers final advice for entrepreneurs transitioning from academia to startups.